Analine derivatives as OSC inhibitors

US6683201B2 · kind B2 · utility

Assignee

• Hoffmann-La Roche Inc. · US

Inventors

• Jean Ackermann · Riehen, CH
• Johannes Aebi · Binningen, CH
• Alexander Chucholowski · San Diego, US
• Henrietta Dehmlow · Weil am Rhein, DE
• Olivier Morand · Hégenheim, FR
• Sabine Wallbaum · Esslingen am Neckar, DE
• Thomas Weller · Binningen, CH

Key dates

• Filing date: Jul 16, 2001
• Grant date: Jan 27, 2004
• Expiry date: Apr 2, 2022

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07C2603/18
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present invention relates to compounds of formula (I) wherein U, Y, V, W, L, X, A1, A2, A3, A4, A5 and A6 are as defined in the description and claims and pharmaceutically acceptable salts and/or pharmaceutically acceptable esters thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with 2,3-oxidosqualene-lanosterol cyclase such as hypercholesterolemia, hyperlipemia, arteriosclerosis, vascular diseases, mycoses, parasite infections, gallstones, tumors and/or hyperproliferative disorders, and/or treatment and/or prophylaxis of impaired glucose tolerance and diabetes.